CompletedNCT01121042
Ondansetron or placebo added to treatment for schizophrenia
About this title
Read the official source — NCT01121042Medication studyAges 18–65Australia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- MelbourneSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 85
- Sponsor
- Bayside Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01121042
- Official title
Show the full official title
Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Melbourne
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Bayside Health.
Did this study involve medication?
Yes. The study involved medication, including Ondansetron and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
